Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade

Brain Res. 1995 Dec 1;701(1-2):13-8. doi: 10.1016/0006-8993(95)00924-3.

Abstract

Dopaminoceptive system alterations in the basal ganglia have been implicated in the pathogenesis of wearing-off fluctuations that complicate levodopa therapy of Parkinson's disease. To evaluate the contribution of glutamatergic mechanisms to the associated changes in striatal efferent pathway function, we examined the ability of N-methyl-D-aspartate (NMDA) receptor blockade to modify the motor response changes produced by chronic levodopa administration to hemiparkinsonian rats. Unilaterally 6-hydroxydopamine lesioned rats, given levodopa/benserazide (25/6.25 mg/kg) twice daily for 3 weeks, developed a progressive shortening in the duration of their motor response to levodopa similar to that occurring in parkinsonian patients with wearing-off phenomenon. The acute systemic administration of MK-801 (0.1 mg/kg) to these animals completely reversed the decrease in turning duration (P < 0.01). Intrastriatal injection of the NMDA antagonist was even more effective in prolonging the levodopa response (P < 0.01), while intranigrally injected MK-801 produced no statistically significant change in the duration of levodopa-induced rotation. Rotational intensity was unaffected by all routes of MK-801 administration. These results suggest that drugs capable of blocking NMDA receptors, especially in striatum, may help ameliorate motor fluctuations in patients with advanced Parkinson's disease.

MeSH terms

  • Animals
  • Antiparkinson Agents / antagonists & inhibitors*
  • Antiparkinson Agents / pharmacology
  • Apomorphine / pharmacology
  • Benserazide / pharmacology
  • Dizocilpine Maleate / administration & dosage
  • Dizocilpine Maleate / pharmacology*
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / pharmacology*
  • Injections
  • Injections, Intraventricular
  • Levodopa / antagonists & inhibitors*
  • Levodopa / pharmacology
  • Male
  • Movement / drug effects
  • Oxidopamine
  • Parkinson Disease, Secondary / physiopathology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
  • Rotation
  • Stereotyped Behavior / drug effects
  • Substantia Nigra

Substances

  • Antiparkinson Agents
  • Excitatory Amino Acid Antagonists
  • Receptors, N-Methyl-D-Aspartate
  • Levodopa
  • Dizocilpine Maleate
  • Benserazide
  • Oxidopamine
  • Apomorphine